As an early adopter of fitness trackers such as the Fitbit, I’ve long appreciated the power of health data. But my recent experience with a continuous glucose monitor (CGM) has done far more to inspire me to look after my health — even as a nondiabetic.
I had heard about the potential of such technology before from the cardiologist Dr. Eric Topol, who serves on the board of Dexcom (NASDAQ:DXCM), and the entrepreneur Tim Ferriss, who has discussed using the technology as a non-diabetic to optimize weight loss and muscle gain.
But I have only recently had the chance to evaluate CGM as part of Dexcom’s “Hello Dexcom” sample program that enables patients to try out the company’s G6 CGM at no cost. The goal of the program is to increase awareness among healthcare providers and consumers.
Get the full story from our sister site, Drug Delivery Business.